Vorinostat
Zolinza (vorinostat) is a small molecule pharmaceutical. Vorinostat was first approved as Zolinza on 2006-10-06. It is used to treat t-cell lymphoma cutaneous in the USA. The pharmaceutical is active against histone deacetylase 1. In addition, it is known to target histone deacetylase 8, histone deacetylase 11, histone deacetylase 6, polyamine deacetylase HDAC10, histone deacetylase 9, histone deacetylase 3, histone deacetylase 5, and histone deacetylase 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| hemic and lymphatic diseases | D006425 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Zolinza
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vorinostat
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZOLINZA | Merck & Co | N-021991 RX | 2006-10-06 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| zolinza | New Drug Application | 2024-11-12 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| t-cell lymphoma cutaneous | — | D016410 | C84.A |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
283 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 9 | 5 | 2 | — | — | 14 |
| Plasma cell neoplasms | D054219 | — | — | 7 | 4 | 2 | — | — | 11 |
| Non-small-cell lung carcinoma | D002289 | — | — | 8 | 7 | 1 | — | — | 11 |
| Lung neoplasms | D008175 | — | C34.90 | 7 | 5 | 1 | — | 1 | 10 |
| Malignant mesothelioma | D000086002 | — | — | 1 | 1 | 1 | — | — | 2 |
| Mesothelioma | D008654 | — | C45 | 1 | 1 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 10 | 12 | — | — | 1 | 17 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 4 | 7 | — | — | — | 9 |
| Neoplasms | D009369 | — | C80 | 8 | 2 | — | — | — | 9 |
| Leukemia | D007938 | — | C95 | 3 | 7 | — | — | — | 8 |
| Myelodysplastic syndromes | D009190 | — | D46 | 2 | 6 | — | — | — | 7 |
| Preleukemia | D011289 | — | — | 2 | 6 | — | — | — | 7 |
| T-cell lymphoma | D016399 | — | — | 4 | 4 | — | — | 1 | 7 |
| Glioblastoma | D005909 | EFO_0000515 | — | 6 | 5 | — | — | — | 7 |
| Syndrome | D013577 | — | — | 2 | 5 | — | — | — | 6 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 2 | 5 | — | — | — | 6 |
Show 42 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Plasmacytoma | D010954 | — | C90.3 | 2 | — | — | — | — | 2 |
| Esophageal neoplasms | D004938 | — | C15 | 1 | — | — | — | 1 | 2 |
| Neurologic manifestations | D009461 | — | — | 1 | — | — | — | — | 1 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | — | — | — | — | 1 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | — | — | — | — | 1 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | — | — | — | — | 1 |
| Esophageal squamous cell carcinoma | D000077277 | — | — | 1 | — | — | — | — | 1 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | — | — | — | — | 1 |
| Intestinal neoplasms | D007414 | — | C26.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pruritus | D011537 | — | L29 | — | — | — | — | 1 | 1 |
| Head and neck neoplasms | D006258 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vorinostat |
| INN | vorinostat |
| Description | Vorinostat is a dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL). It has a role as an EC 3.5.1.98 (histone deacetylase) inhibitor, an apoptosis inducer and an antineoplastic agent. It is a hydroxamic acid and a dicarboxylic acid diamide. It is functionally related to a suberic acid, a hydroxylamine and an aniline. |
| Classification | Small molecule |
| Drug class | enzyme inhibitors: histone deacetylase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(CCCCCCC(=O)Nc1ccccc1)NO |
Identifiers
| PDB | — |
| CAS-ID | 149647-78-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL98 |
| ChEBI ID | 45716 |
| PubChem CID | 5311 |
| DrugBank | DB02546 |
| UNII ID | 58IFB293JI (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 17,763 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,079 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use